Cyto-Facto Inc. provides services for manufacturing, development, and quality control testing of gene and cell preparations

Cyto-Fact Co., Ltd. (Head Office: Chuo-ku, Kobe-City, CEO: Shin Kawamata, hereinafter referred to as CF), which conducts CMO/CDMO business specializing in gene and cell therapy, has raised a total of 300 million yen through the third-party allocation of shares to D3 Bio-Healthcare Fund Investment Limited Partnership No.1 (D3 LLC.: Managing Partner, Tomoya Nagata) and loans from financial institutions.

Please check a link for detailed information.

August. 28. 2023
Cyto-Facto Inc.